Belantamab Mafodotin Combinations in Myeloma — PatSnap Eureka
Belantamab Mafodotin Combination Readouts in Myeloma
GSK's belantamab mafodotin (belamaf) is staging a Phase III comeback after voluntary US withdrawal in 2022. Patent intelligence reveals a broad combination IP architecture spanning proteasome inhibitors, anti-CD38 agents, gamma secretase inhibitors, bispecific antibodies, and checkpoint inhibitors for relapsed/refractory multiple myeloma.
Belamaf Combination Classes in GSK Patent Portfolio
Distinct therapeutic combination categories covered across 10 retrieved GSK patent filings (2021–2023)
From Accelerated Approval to Phase III Resurrection
Belantamab mafodotin (belamaf) is an anti-BCMA antibody-drug conjugate (ADC) developed by GlaxoSmithKline for the treatment of relapsed or refractory multiple myeloma (RRMM). It targets B-cell maturation antigen (BCMA), a protein highly expressed on myeloma cells, and delivers a cytotoxic payload directly to tumour cells. The drug was originally granted accelerated approval but was voluntarily withdrawn from the US market in 2022 following accelerated approval challenges.
Rather than abandoning the programme, GSK has been actively repositioning belamaf through an extensive Phase III combination development programme underpinned by modified dosing strategies. The patent portfolio retrieved via PatSnap Eureka reveals a systematic effort to establish belamaf across multiple combination backbones spanning proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, gamma secretase inhibitors (GSIs), bispecific antibodies, and checkpoint inhibitors.
According to patent filings, combinations such as belamaf with bortezomib and dexamethasone (BVd) are claimed to result in extended progression-free survival (PFS) when compared to treatment that does not include the combination — a key clinical endpoint for regulatory re-engagement. The patent landscape analysis across 10 unique filings assigned exclusively to GlaxoSmithKline Intellectual Property Development Ltd. signals a deliberate, multi-front IP strategy to protect belamaf's re-emergence across the RRMM treatment continuum.
Multiple myeloma remains a significant unmet medical need, with WHO data indicating it accounts for approximately 10% of all haematological malignancies. The BCMA target has become a crowded but validated space, making combination differentiation central to GSK's competitive strategy.
Six Therapeutic Combination Categories in GSK's Belamaf Patent Portfolio
Patent filings reveal a systematic strategy to position belantamab mafodotin across the full RRMM treatment landscape through diverse combination backbones.
BVd, KCd & Bortezomib-Based Regimens
Patent filings cover belamaf in combination with bortezomib and dexamethasone (BVd) and with carfilzomib and dexamethasone (KCd). The BVd combination is specifically claimed to result in extended progression-free survival (PFS) compared to treatment that does not include the combination, representing a key clinical differentiator for regulatory resubmission.
Extended PFS claimed vs. non-combination treatmentBPd, BLd — Pomalidomide & Lenalidomide Backbones
GSK has filed patents covering belamaf in combination with pomalidomide and dexamethasone (BPd) and with lenalidomide and dexamethasone (BLd). These combinations address patients across different lines of prior IMiD exposure and are designed to complement the proteasome inhibitor-based regimens in the broader RRMM treatment continuum.
Covers both pomalidomide & lenalidomide backbonesB-DVd, B-DPd, B-DRd, B-DVMP with Daratumumab
Among the most expansive coverage in the portfolio, GSK patents include belamaf combined with daratumumab across four distinct backbones: B-DVd (daratumumab, bortezomib, dexamethasone), B-DPd (daratumumab, pomalidomide, dexamethasone), B-DRd (daratumumab, lenalidomide, dexamethasone), and B-DVMP (daratumumab, bortezomib, melphalan, prednisone), covering both transplant-eligible and ineligible patient populations.
4 daratumumab quadruplet regimens patentedSynergistic BCMA Upregulation Mechanism
Patent filings disclose that the combination of belantamab mafodotin and a gamma secretase inhibitor (GSI) acts synergistically and may be superior to either agent alone in treating multiple myeloma. The mechanistic rationale: GSIs upregulate BCMA expression in tumour cells, thereby sensitising the cells to treatment with belantamab mafodotin — a pharmacologically elegant approach to overcoming potential resistance.
Synergistic BCMA upregulation mechanism disclosedGSK Belamaf Combination Patent Filing Trends & Coverage Breadth
Visualising the pace and scope of GSK's belantamab mafodotin combination IP strategy, derived from 10 patent filings retrieved via PatSnap Eureka.
Belamaf Combination Patent Filings by Year (2021–2023)
Filing volume peaked in 2022 — the same year belamaf was voluntarily withdrawn from the US market — signalling GSK's immediate pivot to combination repositioning.
Combination Regimen Coverage by Category
Daratumumab-based quadruplet regimens (B-DVd, B-DPd, B-DRd, B-DVMP) represent the largest single combination category in the retrieved patent portfolio.
What the Patent Portfolio Signals About GSK's Belamaf Strategy
Key strategic inferences drawn directly from the retrieved patent filings — not from clinical data or public statements.
Synergistic Mechanistic Rationale for GSI Combinations
Patent filings disclose that the combination of belantamab mafodotin and a gamma secretase inhibitor (GSI) acts synergistically and may be superior to either agent alone in treating multiple myeloma. The mechanism: GSIs upregulate BCMA expression in tumour cells, thereby sensitising the cells to treatment with belantamab mafodotin — a pharmacologically rational approach to enhancing ADC target engagement.
Bispecific Antibody Combinations Signal Forward-Looking IP
GSK has filed patents covering belamaf in combination with bispecific antibodies that bind to BCMA and CD3 (TCB), CD38 and CD3, FcRH5 and CD3, or GPRC5D and CD3. This positions belamaf at the intersection of ADC-mediated cytotoxicity and T-cell redirection — two of the most active modalities in contemporary myeloma drug development, as tracked by PatSnap analytics.
Belantamab Mafodotin Combination Regimens: Patent Coverage Summary
| Regimen Abbreviation | Components | Combination Category | Patent Filing (Example) |
|---|---|---|---|
| BVd | Belantamab mafodotin + bortezomib + dexamethasone | Proteasome Inhibitor | WO2021108661A1 (2021) |
| KCd | Belantamab mafodotin + carfilzomib + dexamethasone | Proteasome Inhibitor | WO2022099014A2 (2022) |
| BPd | Belantamab mafodotin + pomalidomide + dexamethasone | IMiD | WO2022245975A1 (2022) |
| BLd | Belantamab mafodotin + lenalidomide + dexamethasone | IMiD | WO2022261183A1 (2022) |
| B-DVd | Belantamab mafodotin + daratumumab + bortezomib + dexamethasone | Anti-CD38 Quadruplet | WO2022245975A1 (2022) |
| B-DPd | Belantamab mafodotin + daratumumab + pomalidomide + dexamethasone | Anti-CD38 Quadruplet | WO2022245975A1 (2022) |
| B-DRd | Belantamab mafodotin + daratumumab + lenalidomide + dexamethasone | Anti-CD38 Quadruplet | WO2022261183A1 (2022) |
| B-DVMP | Belantamab mafodotin + daratumumab + bortezomib + melphalan + prednisone | Anti-CD38 Quadruplet | WO2022245975A1 (2022) |
| Belamaf + GSI | Belantamab mafodotin + gamma secretase inhibitor | GSI (BCMA upregulator) | US20220331432A1 (2022) |
| Belamaf + Bispecific | Belantamab mafodotin + BCMA×CD3 / CD38×CD3 / FcRH5×CD3 / GPRC5D×CD3 bispecific | Bispecific Antibody | WO2022241355A2 (2022) |
| Belamaf + Checkpoint | Belantamab mafodotin + pembrolizumab or dostarlimab (anti-PD-1/PD-L1/TIGIT) | Checkpoint Inhibitor | WO2022036043A2 (2022) |
Need deeper patent claim analysis for any of these regimens?
PatSnap Eureka provides full claim text, priority dates, and family mapping for every filing above.
Belantamab Mafodotin Combinations in Myeloma — Key Questions Answered
Belantamab mafodotin (belamaf) is an anti-BCMA antibody-drug conjugate (ADC) developed by GlaxoSmithKline (GSK). It targets B-cell maturation antigen (BCMA), which is expressed on multiple myeloma cells, and delivers a cytotoxic payload directly to those cells. It was originally granted accelerated approval but was voluntarily withdrawn from the US market in 2022, and has since been repositioned through an extensive Phase III combination development program underpinned by modified dosing strategies.
GSK's patent filings cover a broad set of belantamab mafodotin combination regimens for relapsed or refractory multiple myeloma (RRMM), including: bortezomib and dexamethasone (BVd), pomalidomide and dexamethasone (BPd), lenalidomide and dexamethasone (BLd), daratumumab plus bortezomib and dexamethasone (B-DVd), daratumumab plus pomalidomide and dexamethasone (B-DPd), daratumumab plus lenalidomide and dexamethasone (B-DRd), daratumumab plus bortezomib, melphalan and prednisone (B-DVMP), carfilzomib and dexamethasone, gamma secretase inhibitors (GSIs), bispecific antibodies targeting BCMA/CD3, CD38/CD3, FcRH5/CD3 or GPRC5D/CD3, and checkpoint inhibitors including pembrolizumab and dostarlimab.
Belantamab mafodotin was voluntarily withdrawn from the US market in 2022 following accelerated approval challenges. GSK has been actively repositioning the drug through an extensive Phase III combination development programme underpinned by modified dosing strategies, with the goal of demonstrating superior efficacy in combination regimens for relapsed or refractory multiple myeloma (RRMM).
Patent filings disclose that the combination of belantamab mafodotin and a gamma secretase inhibitor (GSI) acts synergistically and may be superior to either agent alone in treating multiple myeloma. The mechanism involves the GSI upregulating BCMA expression in tumor cells, thereby sensitizing the cells to treatment with belantamab mafodotin.
GSK's patent filings cover belantamab mafodotin in combination with bispecific antibodies that bind to BCMA and CD3 (TCB), CD38 and CD3, FcRH5 and CD3, or GPRC5D and CD3.
GSK's patent filings for combination therapies in relapsed or refractory multiple myeloma (RRMM) include belantamab mafodotin in combination with anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-TIGIT antibodies, or combinations thereof. Specifically named agents include pembrolizumab and dostarlimab.
Still have questions about belamaf patent intelligence? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About BelamafMap Every BCMA ADC Combination Patent in Real Time
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and competitive intelligence in oncology.
References
- GlaxoSmithKline — WO2021108661A1: Methods of Treating Multiple Myeloma with Belantamab Mafodotin Combinations (BVd, PFS claim)
- GlaxoSmithKline — WO2022245975A1: Methods of Treating Multiple Myeloma (BVd, BPd, BLd, B-DVd, B-DPd, B-DRd, B-DVMP)
- GlaxoSmithKline — WO2022261183A1: Methods of Treating Multiple Myeloma (BVd, BPd, BLd, daratumumab quadruplets)
- GlaxoSmithKline — WO2022099014A2: Methods of Treating Multiple Myeloma (carfilzomib and bortezomib combinations)
- GlaxoSmithKline — US20220331432A1: Combination Therapy Including Anti-BCMA ADCs and Gamma Secretase Inhibitors (synergistic mechanism)
- GlaxoSmithKline — WO2022261199A2: Anti-BCMA Antibody Conjugates, Combinations with a Gamma Secretase Inhibitor
- GlaxoSmithKline — US20220340662A1: Anti-BCMA Antibody Conjugates, Combinations with a Gamma Secretase Inhibitor
- GlaxoSmithKline — WO2022241355A2: Combination Therapy for Treating Cancer (bispecific antibodies: BCMA/CD3, CD38/CD3, FcRH5/CD3, GPRC5D/CD3)
- GlaxoSmithKline — WO2022036043A2: Combination Therapies for Treatment of Multiple Myeloma (anti-PD-1, anti-PD-L1, anti-TIGIT, pembrolizumab, dostarlimab)
- GlaxoSmithKline — US20230218762A1: Methods of Treating Multiple Myeloma (belantamab mafodotin combinations)
- World Health Organization (WHO) — Haematological Malignancies Overview
- National Cancer Institute (NCI) — BCMA and Multiple Myeloma Background
All patent data on this page is sourced from the references above and retrieved via PatSnap's proprietary innovation intelligence platform. This report represents a patent-based snapshot only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.